These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27060927)

  • 61. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
    Zhang M; Zhuang G; Sun X; Shen Y; Wang W; Li Q; Di W
    Diagn Pathol; 2017 Feb; 12(1):16. PubMed ID: 28148293
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
    Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
    Liew PL; Huang RL; Weng YC; Fang CL; Hui-Ming Huang T; Lai HC
    Int J Cancer; 2018 Jul; 143(2):355-367. PubMed ID: 29451304
    [TBL] [Abstract][Full Text] [Related]  

  • 65. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aberrant expression of cdx2 homeobox gene in intraductal papillary-mucinous neoplasm of the pancreas but not in pancreatic ductal adenocarcinoma.
    Yeh TS; Ho YP; Chiu CT; Chen TC; Jan YY; Chen MF
    Pancreas; 2005 Apr; 30(3):233-8. PubMed ID: 15782100
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 70. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
    Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
    Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
    Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
    Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
    Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
    Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin.
    Tada Y; Wada M; Migita T; Nagayama J; Hinoshita E; Mochida Y; Maehara Y; Tsuneyoshi M; Kuwano M; Naito S
    Int J Cancer; 2002 Apr; 98(4):630-5. PubMed ID: 11920626
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.
    Hui RC; Francis RE; Guest SK; Costa JR; Gomes AR; Myatt SS; Brosens JJ; Lam EW
    Mol Cancer Ther; 2008 Mar; 7(3):670-8. PubMed ID: 18347152
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
    Strickland S; Parra-Herran C
    Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
    Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
    Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
    Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T
    Leuk Res; 2018 Apr; 67():99-108. PubMed ID: 29482174
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
    Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
    Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
    Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.